Meiying Zhang Selected Research

Meiying Zhang Research Topics

Disease

21	Neoplasms (Cancer) 01/2022 - 07/2002
7	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 01/2016
4	Breast Neoplasms (Breast Cancer) 01/2021 - 10/2015
3	Ovarian Epithelial Carcinoma 01/2022 - 10/2015
3	Neoplasm Metastasis (Metastasis) 10/2021 - 10/2015
3	Hepatocellular Carcinoma (Hepatoma) 11/2020 - 05/2015
3	Colorectal Neoplasms (Colorectal Cancer) 01/2017 - 01/2017
2	Infections 01/2022 - 08/2014
2	Thyroid Neoplasms (Thyroid Cancer) 01/2021 - 12/2020
1	Sepsis (Septicemia) 01/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022
1	Anaplastic Thyroid Carcinoma 01/2021
1	Glioblastoma (Glioblastoma Multiforme) 01/2021
1	Leukemia 01/2021
1	Lung Neoplasms (Lung Cancer) 01/2021
1	Myasthenia Gravis 01/2021
1	Seizures (Absence Seizure) 11/2020
1	Epilepsy (Aura) 11/2020
1	Insulin Resistance 10/2020
1	Non-alcoholic Fatty Liver Disease 10/2020
1	Liver Neoplasms (Liver Cancer) 03/2020
1	Lymphatic Metastasis 03/2020
1	Esophageal Squamous Cell Carcinoma 03/2020
1	Esophageal Neoplasms (Esophageal Cancer) 03/2020
1	Pruritus (Itching) 01/2020
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2020
1	Impetigo (Impetigo Contagiosa) 01/2020
1	Carcinogenesis 01/2019
1	Reperfusion Injury 01/2018
1	Infarction (Infarctions) 01/2018
1	Ischemia 01/2018
1	Polyploidy 02/2017
1	Aneuploidy (Aneuploid) 02/2017
1	Carcinoma (Carcinomatosis) 01/2016
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2016
1	Sarcoma (Soft Tissue Sarcoma) 10/2015

Drug/Important Bio-Agent (IBA)

4	Pharmaceutical PreparationsIBA 01/2022 - 01/2017
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2016
4	Biomarkers (Surrogate Marker)IBA 10/2020 - 01/2016
3	Transcription Factors (Transcription Factor)IBA 01/2022 - 01/2017
3	RNA (Ribonucleic Acid)IBA 10/2021 - 01/2016
3	Biological ProductsIBA 01/2021 - 07/2002
3	Long Noncoding RNAIBA 12/2020 - 01/2016
3	DNA (Deoxyribonucleic Acid)IBA 03/2020 - 01/2017
3	NucleotidesIBA 12/2017 - 02/2016
2	BerberineIBA 01/2022 - 01/2022
2	IodineIBA 10/2021 - 01/2021
2	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 01/2017
2	CateninsIBA 01/2021 - 12/2017
2	Docetaxel (Taxotere)FDA Link 11/2015 - 05/2015
1	Lysine AcetyltransferasesIBA 01/2021
1	Histone Acetyltransferases (Histone Acetyltransferase)IBA 01/2021
1	AgrinIBA 01/2021
1	AntibodiesIBA 01/2021
1	AZD0156IBA 01/2021
1	EnzymesIBA 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 11/2020
1	Glutamic Acid (Glutamate)FDA Link 11/2020
1	Pentylenetetrazole (Metrazol)IBA 11/2020
1	Pilocarpine (Ocusert)FDA LinkGeneric 11/2020
1	Oncogene Proteins (Oncogene Protein)IBA 11/2020
1	Hormones (Hormone)IBA 10/2020
1	AdiponectinIBA 10/2020
1	Serum AlbuminIBA 10/2020
1	Triglycerides (Triacylglycerol)IBA 10/2020
1	Blood Glucose (Blood Sugar)IBA 10/2020
1	Protein AggregatesIBA 01/2019
1	Protein Isoforms (Isoforms)IBA 01/2019
1	Histone Deacetylase InhibitorsIBA 01/2019
1	Proteasome InhibitorsIBA 01/2019
1	Small Interfering RNA (siRNA)IBA 01/2018
1	HMGB1 Protein (HMG1)IBA 01/2018
1	Thioctic Acid (Lipoic Acid)IBA 01/2018
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2018
1	Caspase 3 (Caspase-3)IBA 01/2018
1	Deubiquitinating EnzymesIBA 01/2018
1	MicellesIBA 12/2017
1	rubusosideIBA 12/2017
1	CurcuminIBA 12/2017
1	ResveratrolIBA 12/2017
1	TrypsinIBA 11/2017
1	Serine Proteases (Serine Protease)IBA 11/2017
1	NF-kappa B (NF-kB)IBA 03/2017
1	hydrogen sulfite (bisulfite)IBA 01/2017
1	Antineoplastic Agents (Antineoplastics)IBA 01/2017
1	Potassium Channels (Potassium Channel)IBA 01/2017
1	Tumor Biomarkers (Tumor Markers)IBA 02/2016
1	GSK1210151AIBA 01/2016
1	Forkhead Box Protein M1IBA 01/2016
1	BI 6727IBA 01/2016
1	Phosphotransferases (Kinase)IBA 01/2016
1	human ERBB2 proteinIBA 10/2015

Therapy/Procedure

4	Therapeutics 11/2020 - 01/2016
1	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2022
1	Complementary Therapies (Alternative Medicine) 01/2022
1	Mongolian Traditional Medicine 01/2020
1	Drug Therapy (Chemotherapy) 01/2019
1	Oral Administration 10/2017
1	Aftercare (After-Treatment) 01/2016